论文部分内容阅读
目的探讨进展性缺血性脑卒中的相关危险因素及其治疗。方法回顾分析我院2009年11月至2011年3月收治的70例进展性缺血性脑卒中患者的临床资料。结果两组治疗3d后、14d后和21d后神经功能缺损评分下降率分别比较,观察组均明显优于对照组(P<0.05)。观察组和对照组总有效率分别为91.89%、81.82%,2组比较,差异有统计学意义(P<0.05)。结论高血压、高血糖、高血脂及高纤维蛋白原是进展性缺血性脑卒中的主要危险因素;依达拉奉治疗缺血性进展性卒中安全有效。
Objective To explore the related risk factors and treatment of progressive ischemic stroke. Methods The clinical data of 70 patients with progressive ischemic stroke admitted to our hospital from November 2009 to March 2011 were retrospectively analyzed. Results The decreasing rate of neurological deficit scores of the two groups after 3d, 14d and 21d respectively was significantly better than that of the control group (P <0.05). The total effective rate in the observation group and the control group was 91.89% and 81.82% respectively. There was significant difference between the two groups (P <0.05). Conclusions Hypertension, hyperglycemia, hyperlipidemia and hyperfibrinogen are the major risk factors of progressive ischemic stroke. Edaravone is safe and effective in treating ischemic stroke.